Fibrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 2022 | 73 pages | ID: F03B552C352BEN
Global Markets Direct

Abstracts

Fibrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Drugs In Development, 2022, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape.

Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Fibrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 8, 5, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosarcoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Fibrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Fibrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Fibrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosarcoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Fibrosarcoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Fibrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Fibrosarcoma - Overview
Fibrosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrosarcoma - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Alphamab Oncology
AntiCancer Inc
Apollomics Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Bicycle Therapeutics Plc
BioMed Valley Discoveries Inc
Calithera Biosciences Inc
F. Hoffmann-La Roche Ltd
Intezyne Inc
Lytix Biopharma AS
Mediolanum farmaceutici SpA
Orum Therapeutics Inc
Paranta Biosciences Ltd
Pharma Mar SA
Philogen SpA
PTC Therapeutics Inc
QBiotics Group Ltd
Shanghai Junshi Bioscience Co Ltd
Veltion Therapeutics LLC
Y-mAbs Therapeutics Inc
Fibrosarcoma - Drug Profiles
A-1R - Drug Profile
Product Description
Mechanism Of Action
History of Events
anlotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antisense Oligonucleotides to Inhibit Rho-GAP for Colon Cancer and Fibrosarcoma - Drug Profile
Product Description
Mechanism Of Action
apatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
APL-502 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZD-1390 - Drug Profile
Product Description
Mechanism Of Action
AZD-7648 - Drug Profile
Product Description
Mechanism Of Action
BT-5528 - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
CNV-NT - Drug Profile
Product Description
Mechanism Of Action
History of Events
daunorubicin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
DP-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Inhibit ATF4 for Oncology and Fibrosis - Drug Profile
Product Description
Mechanism Of Action
DTT - Drug Profile
Product Description
Mechanism Of Action
ecubectedin - Drug Profile
Product Description
Mechanism Of Action
History of Events
ELB-021 - Drug Profile
Product Description
Mechanism Of Action
History of Events
entrectinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
envafolimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
fibromun - Drug Profile
Product Description
Mechanism Of Action
History of Events
larotrectinib sulfate - Drug Profile
Product Description
Mechanism Of Action
History of Events
MEDI-5395 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MI-130110 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Nivatrotamab - Drug Profile
Product Description
Mechanism Of Action
History of Events
pamiparib - Drug Profile
Product Description
Mechanism Of Action
History of Events
RT-11i - Drug Profile
Product Description
Mechanism Of Action
sapanisertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
selitrectinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
tigilanol tiglate - Drug Profile
Product Description
Mechanism Of Action
History of Events
toripalimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
unesbulin - Drug Profile
Product Description
Mechanism Of Action
Fibrosarcoma - Dormant Projects
Fibrosarcoma - Product Development Milestones
Featured News & Press Releases
May 11, 2020: TRACON Pharmaceuticals announces successful type B meeting with FDA for pivotal study of envafolimab in sarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Fibrosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fibrosarcoma - Pipeline by Advenchen Laboratories LLC, 2022
Fibrosarcoma - Pipeline by Alphamab Oncology, 2022
Fibrosarcoma - Pipeline by AntiCancer Inc, 2022
Fibrosarcoma - Pipeline by Apollomics Inc, 2022
Fibrosarcoma - Pipeline by AstraZeneca Plc, 2022
Fibrosarcoma - Pipeline by Bayer AG, 2022
Fibrosarcoma - Pipeline by BeiGene Ltd, 2022
Fibrosarcoma - Pipeline by Bicycle Therapeutics Plc, 2022
Fibrosarcoma - Pipeline by BioMed Valley Discoveries Inc, 2022
Fibrosarcoma - Pipeline by Calithera Biosciences Inc, 2022
Fibrosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Fibrosarcoma - Pipeline by Intezyne Inc, 2022
Fibrosarcoma - Pipeline by Lytix Biopharma AS, 2022
Fibrosarcoma - Pipeline by Mediolanum farmaceutici SpA, 2022
Fibrosarcoma - Pipeline by Orum Therapeutics Inc, 2022
Fibrosarcoma - Pipeline by Paranta Biosciences Ltd, 2022
Fibrosarcoma - Pipeline by Pharma Mar SA, 2022
Fibrosarcoma - Pipeline by Philogen SpA, 2022
Fibrosarcoma - Pipeline by PTC Therapeutics Inc, 2022
Fibrosarcoma - Pipeline by QBiotics Group Ltd, 2022
Fibrosarcoma - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Fibrosarcoma - Pipeline by Veltion Therapeutics LLC, 2022
Fibrosarcoma - Pipeline by Y-mAbs Therapeutics Inc, 2022
Fibrosarcoma - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Fibrosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022